Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin + doxorubicin versus CAV or topotecan for small cell lung cancer
RBR-22fy6tPhase 3Not yet recruiting
- Sponsor
- Hospital de Caridade de Ijuí
- Start
- Feb 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lurbinectedin, doxorubicin, cyclophosphamide, vincristine and topotecan in small cell lung cancer (SCLC) and cancer of unknown primary (CUP) (2 arms), sponsored by Hospital de Caridade de Ijuí. Planned start Feb 2017; status: not yet recruiting.
02
Drugs
lurbinectedindoxorubicincyclophosphamidevincristinetopotecan
03
Conditions
small cell lung cancer (SCLC)cancer of unknown primary (CUP)
Beyond the preview
Go deeper on RBR-22fy6t.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-22fy6t.